ANTI-AGING
HTN OBESITY MENS & WOMEN'S HEALTH ASA STATUS
ANTI-AGING
HTN OBESITY MENS & WOMEN'S HEALTH ASA STATUS
The only antiaging interventions with solid human outcome data are lifestyle measures (exercise, smoking cessation, healthy diet, weight control, sleep) and, for skin, daily broad-spectrum sunscreen plus a topical retinoid. Drug "longevity" protocols (metformin, rapamycin, senolytics, NAD+ boosters) are still investigational in healthy people.
[1-2]
Below, the evidence is split into systemic (healthspan) and skin aging.
Systemic aging and healthspan: strongest evidence
Aerobic and resistance exercise: linked to less age-related disease, lower biological-age markers and longer lifespan. A common target is 150 min/week of moderate aerobic activity plus resistance training at least 2 days/week.
[3]
Not smoking and limiting alcohol: both are linked to large gains in years lived without chronic disease or disability.
[3-4]
Mediterranean or DASH-style diet: linked to fewer adverse clinical events and less long-term weight gain.
[3]
Caloric restriction / weight loss: in a meta-analysis of weight-loss trials, all-cause mortality fell. In CALERIE, 2 years of restriction in non-obese adults lowered cardiovascular risk, inflammation and biological-age markers. The downsides are loss of lean mass and bone density, and long-term survival effects in non-obese people are unknown.
[1][3]
Multicomponent programs (diet, sleep, exercise, relaxation): one small trial reported a 3.23-year lower epigenetic age. Epigenetic clocks are surrogate markers, not clinical outcomes.
[4]
Standard prevention: treating blood pressure, lipids and glucose, vaccinations, cancer screening, and staying socially connected. These remain the most reliable ways to extend healthspan.
Investigational drug strategies (not recommended for routine antiaging use)
Intervention
Rationale
Human evidence
References
GLP-1 RAs (semaglutide, tirzepatide)
Mimic caloric restriction
Proven benefit only in their approved indications (obesity, T2DM, CVD), not for aging itself
[1, 5]
Metformin
AMPK/mTOR effects, less inflammation
Observational data look favorable; trial data are mixed; TAME-type trials still running
[1-2]
Rapamycin/rapalogs
mTOR inhibition, more autophagy
Better vaccine response; immunosuppression risk
[1]
Senolytics (dasatinib + quercetin, fisetin)
Clear senescent cells
Early-phase studies only; results inconsistent
[1-2]
NAD+ precursors (NR, NMN)
Restore NAD+
Limited human data, mixed results
[2]
Testosterone, growth hormone, DHEA and "biohacking" stacks should not be used for antiaging in people without a deficiency. They have no outcome benefit and carry real risks.
Skin aging: evidence-based regimen
Daily broad-spectrum sunscreen with strong UVA coverage. This is the foundation, since UV exposure is the main driver of photoaging.
[6]
Topical retinoid at night. Tretinoin is the gold standard, usually at 0.05–0.1%. In a network meta-analysis of 23 RCTs, tretinoin and topical isotretinoin had the best balance of efficacy and safety. Retinol helped fine wrinkles and pigmentation, and tazarotene worked best for coarse wrinkles but caused more irritation. Start 2–3 nights a week to limit irritation, and avoid in pregnancy.
[7-10]
Optional add-ons: vitamin C/E/ferulic acid serums, niacinamide, AHAs, moisturizers. Their supporting evidence is weaker and often industry-funded.
[11-12]
Procedures (lasers, chemical peels, neuromodulators, fillers): used for established photodamage, chosen by the patient's goals.
The forest plot from the network meta-analysis compares topical agents with placebo for fine wrinkles:
Figure 2. (A) Network plot for fine wrinkle.
Comparative efficacy of topical interventions for facial photoaging: a network meta-analysis. Sci Rep. July 24, 2025.
Used under license from Springer Nature
1.
Geroscience: A Translational Review.
The Journal of the American Medical Association. 2025. Kritchevsky SB, Cummings SR.Review
2.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023. Espinoza SE, Khosla S, Baur JA, de Cabo R, Musi N.
3.
Biological Versus Chronological Aging: JACC Focus Seminar.
Journal of the American College of Cardiology. 2020. Hamczyk MR, Nevado RM, Barettino A, Fuster V, Andrés V.Review
4.
Non-pharmaceutical interventions and epigenetic aging in adults: Protocol for a scoping review.
PloS One. 2024. Liebich A, Zheng S, Schachner T, et al.
5.
FDA Orange Book. 2026.
6.
The impact of the six pillars of lifestyle medicine on the biology of skin aging.
Frontiers in Aging. 2026. Piquero-Casals J, Cruz AR, Ponti-Concetti L, et al.RecentReview
7.
Skin Ageing and Topical Rejuvenation Strategies.
The British Journal of Dermatology. 2023. Griffiths TW, Watson REB, Langton AK.Review
8.
Photoaging: Current Concepts on Molecular Mechanisms, Prevention, and Treatment.
American Journal of Clinical Dermatology. 2025. Kaltchenko MV, Chien AL.Review
9.
Perimenopausal Nuances in the Aging Face: A Comprehensive Perspective.
Facial Plastic Surgery & Aesthetic Medicine. 2026. Pennington L, Haver MC, Fabi S.Recent
10.
Comparative efficacy of topical interventions for facial photoaging: a network meta-analysis.
Scientific Reports. 2025. Lin L, Chen X, Liu C, et al.SR
11.
Topical and Systemic Skin Aging Interventions: Evidence, Pitfalls and Perspectives.
Biochemical Pharmacology. 2026. Gürtler AL, Sirois JP, Heckenbach IJ, et al.RecentReview
12.
mRNA Therapeutics for Skin Rejuvenation: From Aging Atlases to Clinical Translation.
Experimental Dermatology. 2026. Boncimino F, Sol S, Todorova K, Mandinova A.RecentReview
All three are prevented and managed mainly through lifestyle measures and risk-factor control; no drug is approved for aging, sarcopenia or dementia prevention.
1. Healthspan and biological age
Exercise regularly: at least 150 min/week of aerobic activity plus resistance training. Eat a Mediterranean or DASH-style diet, don't smoke, keep alcohol low, maintain a healthy weight, sleep well, and stay socially connected. Control blood pressure, lipids and glucose, and stay current on vaccines and screening. The AHA's Life's Essential 8 framework covers most of this.
[1-2]
Epigenetic clocks are research tools and should not guide treatment.
2. Sarcopenia and frailty
Screen with grip strength, gait speed or chair-rise time.
[3]
Progressive resistance training is first-line, and multicomponent exercise (adding balance and aerobic work) is reasonable.
[4-5]
Protein intake of 1.0–1.5 g/kg/day is an adjunct and works best combined with resistance training.
[4][6]
Replete vitamin D only if the patient is deficient.
[6]
Make sure total calorie intake is adequate, and review medications. No drug is approved for sarcopenia; candidates such as bimagrumab remain investigational.
[7]
3. Cognitive aging and dementia
About 45% of dementia risk comes from 14 modifiable factors.
[8]
Key steps:
Treat hypertension. In SPRINT-MIND, intensive control reduced MCI.
[9]
Treat high LDL, diabetes, obesity and depression, and stop smoking.
[2]
Correct hearing and vision loss.
[8]
Encourage exercise, a Mediterranean or MIND diet, good sleep, social engagement and mental stimulation.
[1]
Multidomain programs (FINGER, US POINTER, SMARRT) give modest cognitive benefits in at-risk adults. Whether they lower dementia incidence is not yet proven.
[10-11]
4 items
Meta-analysis of selected risk and protective factors for incident AD (n = 31).
BMC Public HealthJune 24, 2014
Temporal trends in population attributable fraction of 12 modifiable risk factors for dementia, 2004–2019, by risk factor.
BMC MedicineJune 26, 2024
Figure 2.Muscle Health Management Pathway for Older Adults: Screening, Risk Stratification, Targeted Intervention, and Outcome Tracking A simple bedside algorithm screening test (grip strength, gait speed, or chair rise) triggers more extensive diagnostic work for sarcopenia to stratify patients into low-, moderate-, or high-risk pathways.
JACCDecember 1, 2025
Comparison 3: Multi‐domain interventions for cognitive decline, Outcome 1: Comparison 3.
Cochrane Database of Systematic ReviewsNovember 8, 2021
1.
2025 Advances in Brain Health: Brain Health as Capital for Vascular and Cognitive Resilience.
Stroke. 2026. Rundek T, Du R.Recent
2.
An Ounce of Prevention: The Growing Need for Preventive Neurologists.
Neurology. 2025. Sabayan B, Boden-Albala B, Rost NS.Opinion
3.
Skeletal Muscle-Cardiac Muscle Aging: Shared Mechanisms and Multimodal Interventions.
JACC. Advances. 2025. Kalra K, Berchie P, Singh S, et al.RecentReview
4.
Toward the recognition and management of sarcopenia in routine clinical care.
Nature Aging. 2021. Dent E, Woo J, Scott D, Hoogendijk EO.Review
5.
The Impact of Lifestyle Factors Across the Life Course on Sarcopenia and Physical Frailty.
Current Opinion in Clinical Nutrition and Metabolic Care. 2025. Yang DZ, Kua J, Lim WS.Review
6.
The Journal of Nutrition. 2026. Dharmansyah D, Suparto TA, Salasa S, Hikmat R, Pratama A.Recent
7.
Molecular Neurobiology. 2026. Xue F, Xu H, Yao X, et al.RecentReview
8.
Lancet. 2026. Serrano-Pozo A, Escott-Price V, Grinberg LT, et al.RecentReview
9.
Annals of Internal Medicine. 2024. Oh ES.Review
10.
Nearly Half of Dementia Cases May Be Preventable—Here’s What the Research Says So Far.
The Journal of the American Medical Association. 2026. Rubin R.RecentOpinion
11.
Journal of the American College of Cardiology. 2026. Alexander KP, Damluji AA, Erqou S, et al.RecentGuideline
12.
BMC Public Health. 2014. Beydoun MA, Beydoun HA, Gamaldo AA, et al.SR
13.
BMC Medicine. 2024. Chen S, Underwood BR, Cardinal RN, et al.
14.
Multi‐domain interventions for the prevention of dementia and cognitive decline.
Cochrane Database of Systematic Reviews. 2021. Melanie Hafdi, Marieke P. Hoevenaar-Blom, Edo Richard
The American College of Cardiology (ACC)/American Heart Association (AHA) 2025 guideline classifies blood pressure into four categories based on average office BP measurements:
Normal: <120 mm Hg systolic and <80 mm Hg diastolic [1]
Elevated: 120–129 mm Hg systolic and <80 mm Hg diastolic [1]
Stage 1 hypertension: 130–139 mm Hg systolic or 80–89 mm Hg diastolic [1]
Stage 2 hypertension: ≥140 mm Hg systolic or ≥90 mm Hg diastolic [1]
When systolic and diastolic values fall into different categories, the higher category applies. Also clinically important:
Severe hypertension: >180/120 mm Hg — if without acute target-organ damage, managed in the outpatient setting with timely oral therapy; with acute target-organ damage this constitutes a hypertensive emergency.
Treatment goal is <130/80 mm Hg for most adults
Overweight: 25.0–29.9
Obesity Class I: 30.0–34.9
Obesity Class II: 35.0–39.9
Severe Obesity (Class III): ≥40.0
Super Obesity: ≥50.0
Super-Super Obesity: ≥60.0
All BMI categories
Lifestyle therapy: calorie reduction, physical activity, behavioral intervention
BMI ≥30 (or ≥27 with obesity-related comorbidity)
Anti-obesity medications:
Tirzepatide
Semaglutide
Liraglutide
Phentermine/Topiramate
Naltrexone/Bupropion
Orlistat
BMI ≥35–40 (depending on comorbidities)
Consider metabolic/bariatric surgery:
Sleeve Gastrectomy
Roux-en-Y Gastric Bypass
BMI is a screening tool, not a direct measure of body fat.
Health risk assessment should also consider body composition, muscle mass, age, sex, fat distribution, and obesity-related comorbidities.
Overweight: 25.0–29.9
Obesity Class I: 30.0–34.9
Obesity Class II: 35.0–39.9
Severe Obesity (Class III): ≥40.0
Super Obesity: ≥50.0
Super-Super Obesity: ≥60.0
All BMI categories
Lifestyle therapy: calorie reduction, physical activity, behavioral intervention
BMI ≥30 (or ≥27 with obesity-related comorbidity)
Anti-obesity medications:
Tirzepatide
Semaglutide
Liraglutide
Phentermine/Topiramate
Naltrexone/Bupropion
Orlistat
BMI ≥35–40 (depending on comorbidities)
Consider metabolic/bariatric surgery:
Sleeve Gastrectomy
Roux-en-Y Gastric Bypass
BMI is a screening tool, not a direct measure of body fat.
Health risk assessment should also consider body composition, muscle mass, age, sex, fat distribution, and obesity-related comorbidities.
A
Almonds: Provide Vitamin E, magnesium, and protein.
Avocado: Pack healthy monounsaturated fats and potassium.
Asparagus: Deliver chromium, fiber, and folate.
B
Broccoli: High in sulforaphane, fiber, and Vitamin C.
Blueberries: Loaded with antioxidants and low-glycemic carbohydrates.
Black Beans (Dry/Boiled): Packed with plant protein, fiber, and iron.
C
Chicken Breast: Packed with lean protein and selenium.
Citrus Fruits (Oranges/Limes): Lactose-free choice providing Vitamin C to lower cortisol.
Cherries: Rich in anthocyanins to reduce muscle soreness and inflammation.
D
Dark Leafy Greens: Provide iron, magnesium, and nitrates.
Dark Chocolate (85%+): Supplies magnesium, antioxidants, and healthy fats.
E
Eggs: Ultimate source of leucine, protein, and healthy fats.
Edamame (Fresh/Frozen): Offers plant-based protein, iron, and fiber.
F
Fish (Fresh/Frozen): Supplies ultra-lean protein and omega-3 fatty acids.
Salmon: Boosts fat loss via omega-3s.
Tuna: High-density lean protein source.
Cod: Low-calorie, pure muscle-building protein.
Flaxseeds: High in lignans, fiber, and alpha-linolenic acid.
Ten key women's health facts and ten key men's health facts, each anchored to a specific statistic from the literature.
Women's health
Average age of menopause is ~51–52 years in the US (mean 51.4; pooled global mean age at natural menopause 50.5 years), with ~90% occurring between 45 and 56.
[1-3]
Average age of menarche is ~12.9 years and has trended earlier over generations (13.5 years for women born before 1930 vs 12.6 years for those born 1970–1984).
[2]
Cardiovascular disease is the leading cause of death in women, not breast cancer; >62 million US women have some form of CVD or hypertension (~45% prevalence), and risk rises sharply after menopause.
[3-4]
Heart disease (21%) and cancer (20%) are the top two causes of death, followed by stroke (6%) and Alzheimer disease (5%) — stroke and Alzheimer disease rank higher in women than in men.
[5]
Female life expectancy is 81.8 years (2023), about 6 years longer than males (75.8 years).
[5]
Breast cancer screening: mammography is recommended every 1–2 years starting at age 40 (USPSTF/AAFP biennial; ACS annual from 45).
[6-7]
Osteoporosis screening with DXA is recommended for all women ≥65; diagnosis is a T-score ≤ −2.5.
[6]
Cervical cancer screening runs from age 21 to 65 — Pap every 3 years (21–29), then Pap/HPV co-testing every 5 years (30–65), stopping at 65 with adequate prior negatives.
[6][8]
Mean age at first birth has risen from 24.8 years (born 1940–49) to 27.3 years (born 1970–84), with nulliparity increasing from 14% to 22%.
[2]
Reproductive lifespan (menarche to menopause) is lengthening — up to ~40 years in recent birth cohorts, driven largely by later menopause.
[2][9]
Men's health
Median age at prostate cancer diagnosis is 67 years; >85% of new cases occur after age 60.
[10-11]
Prostate cancer is the most commonly diagnosed cancer in men and the second leading cause of male cancer death (~35,000 US deaths/year).
[10][12]
Autopsy prevalence is high and age-dependent: 59% of men older than 79 have histologic evidence of prostate cancer, underscoring that many cancers are indolent.
[10]
Racial disparity is marked: prostate cancer incidence is 1.7× and mortality ~2.1× higher in Black men than White men.
[10][12]
Male life expectancy is 75.8 years (2023), ~6 years shorter than women, and the gender gap has widened (from 4.8 to ~5.8 years, 2010–2021).
[5][13]
Heart disease (23%) and cancer (20%) are the leading causes of male death, followed by unintentional injuries (9%).
[5]
Unintentional injuries disproportionately drive the male mortality gap — mostly drug overdoses and transport injuries — accounting for a large share of the widening life-expectancy difference.
[13]
PSA screening is a shared-decision discussion for ages 55–69, not routine, with screening generally stopped after age 75 (AUA suggests 2–4 year intervals).
[12][14]
More than 50% of prostate cancer risk is heritable, per Northern European twin studies.
[10]
Colorectal cancer screening begins at 45 for both sexes (men and women, ages 45–75), via stool-based or structural tests.
[8]
American Society of Anesthesiologists (ASA) Physical Status Classification (Expanded):
ASA I: Normal healthy patient with no systemic disease.
Examples: Non-smoker, no alcohol or minimal use, BMI <25, normal blood pressure (<120/80), no medications, excellent functional capacity.
ASA II: Patient with mild systemic disease without significant functional limitation.
Examples: Controlled hypertension (e.g., BP <140/90 on medication), well-controlled type 2 diabetes (HbA1c ~6–7%), mild obesity (BMI 30–34.9), pregnancy, social alcohol use, current smoker without COPD, mild asthma, or mild OSA not requiring CPAP.
ASA III: Patient with severe systemic disease with substantive functional limitations.
Examples: Poorly controlled hypertension (BP ≥160/100), diabetes with HbA1c >8% or with complications (neuropathy), morbid obesity (BMI ≥40), chronic obstructive pulmonary disease (COPD), obstructive sleep apnea requiring CPAP/NIV, chronic kidney disease stage 3+, history of MI >3 months ago, chronic anticoagulation (e.g., atrial fibrillation on warfarin/DOAC), significant anemia, or active tobacco use with end-organ impact.
ASA IV: Patient with severe systemic disease that is a constant threat to life.
Examples: Recent MI (<3 months), unstable angina, decompensated heart failure (EF <30%), severe COPD with frequent exacerbations or oxygen dependence, advanced renal failure requiring dialysis, uncontrolled diabetes with end-organ damage, sepsis, or severe valvular disease.
ASA V: Moribund patient not expected to survive without the operation.
Examples: Ruptured abdominal aortic aneurysm, massive trauma, intracranial hemorrhage with mass effect, ischemic bowel with hemodynamic instability.
ASA VI: Brain-dead patient whose organs are being removed for donor purposes.
Modifier:
“E” (Emergency): Added to any classification when immediate intervention is required (e.g., ASA III-E, ASA IV-E), indicating increased perioperative risk due to urgency and limited optimization time.